Metis TechBio (HKG:7666) said its underwriters fully exercised the overallotment option for its Hong Kong initial public offering, while the stabilization period ended on June 5, according to a same-day filing with the Hong Kong bourse.
The AI-driven nanotechnology company issued nearly 30.2 million H shares at HK$10.50 per share, generating additional net proceeds of about HK$304.2 million.
The overallotment option was exercised after the same number of shares were over-allocated by the underwriters in the international offering.
Metis TechBio said its public float remained in compliance with Hong Kong listing requirements following the exercise of the overallotment option.